Novo Says May Take Years to Comply With FDA Request

Feb. 11 (Bloomberg) -- Novo Nordisk A/S Chief Executive Officer Lars Rebien Soerensen discusses the U.S. Food and Drug Administration's decision not to approve the insulin maker's Tresiba diabetes treatment, saying more data on heart safety is needed. He talks from Copenhagen with Francine Lacqua on Bloomberg Television's "On the Move." (Source: Bloomberg)
Senate on Verge of Adopting H.R.22 Drive Act
19:05 - The U.S. Senate advanced its version of a long-term highway funding bill Wednesday as Congress prepares a stopgap measure to keep funds flowing for the next three months. Bloomberg's Ramy Inocencio reports on "Bloomberg Markets." (Source: Bloomberg)
  • Gold Falls to 2010 Prices, What's Next?
  • Will Fed Hike Rates Before September?
  • @TheStalwart's Killer Chart: The Shanghai Did What?